Needs in paediatric Rheumatology: The PRINTO perspective

Research output: Contribution to journalArticle

Abstract

Pediatric rheumatic diseases (PRD) encompass an heterogeneous group of rare diseases, ranging from juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) to juvenile dermatomyositis (JDM) and others. The PRD constitute a small market which is of little interest for pharmaceutical industries. Difficulties in operating in this specific area relate to problems which are peculiar to children, such as specific methods for the assessment of the primary outcome, or paediatric formulations, with the need of setting large networks in order to collect in a reasonable time frame an adequate number of patients.

Original languageEnglish
Pages (from-to)105-107
Number of pages3
JournalPharmaceuticals Policy and Law
Volume12
Issue number1-2
DOIs
Publication statusPublished - 2010

Fingerprint

Rheumatology
Pediatrics
Rheumatic Diseases
Juvenile Arthritis
Drug Industry
Rare Diseases
Systemic Lupus Erythematosus
Outcome Assessment (Health Care)

Keywords

  • JDM
  • JIA
  • JSLE
  • Paediatric
  • PRINTO
  • rheumatic disease

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Needs in paediatric Rheumatology : The PRINTO perspective. / Ruperto, Nicolino.

In: Pharmaceuticals Policy and Law, Vol. 12, No. 1-2, 2010, p. 105-107.

Research output: Contribution to journalArticle

@article{cfee66546daf4cb7819c91598ac23aa2,
title = "Needs in paediatric Rheumatology: The PRINTO perspective",
abstract = "Pediatric rheumatic diseases (PRD) encompass an heterogeneous group of rare diseases, ranging from juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) to juvenile dermatomyositis (JDM) and others. The PRD constitute a small market which is of little interest for pharmaceutical industries. Difficulties in operating in this specific area relate to problems which are peculiar to children, such as specific methods for the assessment of the primary outcome, or paediatric formulations, with the need of setting large networks in order to collect in a reasonable time frame an adequate number of patients.",
keywords = "JDM, JIA, JSLE, Paediatric, PRINTO, rheumatic disease",
author = "Nicolino Ruperto",
year = "2010",
doi = "10.3233/PPL-2010-0279",
language = "English",
volume = "12",
pages = "105--107",
journal = "Pharmaceuticals Policy and Law",
issn = "1389-2827",
publisher = "IOS Press",
number = "1-2",

}

TY - JOUR

T1 - Needs in paediatric Rheumatology

T2 - The PRINTO perspective

AU - Ruperto, Nicolino

PY - 2010

Y1 - 2010

N2 - Pediatric rheumatic diseases (PRD) encompass an heterogeneous group of rare diseases, ranging from juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) to juvenile dermatomyositis (JDM) and others. The PRD constitute a small market which is of little interest for pharmaceutical industries. Difficulties in operating in this specific area relate to problems which are peculiar to children, such as specific methods for the assessment of the primary outcome, or paediatric formulations, with the need of setting large networks in order to collect in a reasonable time frame an adequate number of patients.

AB - Pediatric rheumatic diseases (PRD) encompass an heterogeneous group of rare diseases, ranging from juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) to juvenile dermatomyositis (JDM) and others. The PRD constitute a small market which is of little interest for pharmaceutical industries. Difficulties in operating in this specific area relate to problems which are peculiar to children, such as specific methods for the assessment of the primary outcome, or paediatric formulations, with the need of setting large networks in order to collect in a reasonable time frame an adequate number of patients.

KW - JDM

KW - JIA

KW - JSLE

KW - Paediatric

KW - PRINTO

KW - rheumatic disease

UR - http://www.scopus.com/inward/record.url?scp=78049391997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049391997&partnerID=8YFLogxK

U2 - 10.3233/PPL-2010-0279

DO - 10.3233/PPL-2010-0279

M3 - Article

AN - SCOPUS:78049391997

VL - 12

SP - 105

EP - 107

JO - Pharmaceuticals Policy and Law

JF - Pharmaceuticals Policy and Law

SN - 1389-2827

IS - 1-2

ER -